Table 4.
CAR-T and CAR-NK therapies in preclinical and early clinical stage
| Name | Institute/ Company | Type | Phase/ clinical trial ID | Reference/ Patent |
|---|---|---|---|---|
| T60c | Cancer Hospital Chinese Academy of Medical Sciences | CAR-T | Phase 1/2/ NCT06082557 | Not applicable |
| MT-302 | Myeloid Therapeutics | CAR-T | Phase 1/ NCT05969041 | Not applicable |
| Immunomedics anti-Trop-2 CAR | Immunomedics | CAR-T | Preclinical | US20160361360 |
| Trop2/PD-L1 CAR-T | Nanjing Medical University | CAR-T | Preclinical | 81 |
| Trop2-CAR-NK | M.D. Anderson Cancer Center | CAR-NK | Phase 1/2/ NCT05922930 | Not applicable |
| Trop2-CAR | German Cancer Research Center | CAR-NK | Preclinical | 82 |
NK, natural killer; CAR, chimeric antigen receptor.